GlassScriptPhysician profile
Nikhil Gupta
NPI 1982058152
$2,220.57
in general payments reported to CMS, 2019-2025
17 companies · $567 in 2025
The $567 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2022: $83.63 · 2023: $714 · 2024: $737 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $763.05 | 2022-2025 | |
| Gilead Sciences, INC. | $433.19 | 2022-2025 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $250.00 | 2023-2024 | Eliquis |
| Janssen Biotech, INC. | $139.68 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $120.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $119.05 | 2019 | |
| Phathom Pharmaceuticals, INC. | $86.10 | 2024-2025 | Voquezna |
| Pfizer INC. | $42.58 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.85 | 2023-2025 | Xifaxan, Relistor |
| Merck Sharp & Dohme LLC | $38.60 | 2023-2024 | Dificid, Delstrigo, Pifeltro |
| Regeneron Healthcare Solutions, INC. | $33.78 | 2023 | Dupixent |
| Genzyme Corporation | $32.97 | 2022 | |
| Qiagen, LLC | $32.68 | 2024 | |
| Ardelyx, INC. | $32.11 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $20.77 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $19.13 | 2024 | Clenpiq |
| Harmony Biosciences LLC | $17.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.